Adjuvant therapy of melanoma

Seminars in Surgical Oncology

Volumn 14, Issue 4, 1998, Pages 302-310

  Agarwala, Sanjiv S ^a   Kirkwood, John M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adjuvant therapy; BCG vaccine; Clinical trials; Cost benefit analysis; Dacarbazine; Disease free survival; GM(2) ganglioside; Immunotherapy; Interferons; Levamisole; Megestrol acetate; Melanoma; Quality of life; Recurrence; Skin neoplasms; Tumor associated antigens; Vaccines; Vitamin A

Indexed keywords

BCG VACCINE; CARMUSTINE; CISPLATIN; CORYNEBACTERIUM PARVUM EXTRACT; CYCLOPHOSPHAMIDE; DACARBAZINE; GAMMA INTERFERON; GANGLIOSIDE GM2; HLA A1 ANTIGEN; HLA A2 ANTIGEN; KEYHOLE LIMPET HEMOCYANIN; LEVAMISOLE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEGESTROL ACETATE; MELACINE; MELANOMA VACCINE; PHOSPHORYL LIPID A; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; RETINOL; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE; TOPICAL DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; BCG VACCINE; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INTERFERONS; MELANOMA; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0031920823     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199806)14:4<302::AID-SSU6>3.0.CO;2-6     Document Type: Review

References (57)

1. Buzaid AC, Ross MI, Balch CM, et al.: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15:1039-1051.
2. Goldie JH: Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987; 14:1-7.
3. Gutterman JU, Mavligit G, McBride C, et al.: Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet 1973; 1(804):1208-1212.
4. Gutterman JU, Richman SP, McBride CM, et al.: Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival. Recent Results Cancer Res 1978; 68:359-362.
5. Morton DL, Eilber FR, Holmes EC, et al.: BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974; 180:635-643.
6. Veronesi U, Adamus J, Aubert C, et al.: A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307:913-916.
7. Cascinelli N, Rümke P, MacKie R, et al.: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 1989; 28:282-286.
8. Czarnetzki BM, Macher E, Suciu S, et al.: Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment m a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993; 29A:1237-1242.
9. Halpern BN, Biozzi G, Stiffel C, Mouton D: Inhibition of tumour growth by administration of killed Cornyebacterium parvum. Nature 1966; 212:853-854.
10. Lipton A, Harvey HA, Lawrence B, et al.: Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 1983; 51:57-60.
11. Balch CM, Murray DR, Presant C, et al.: A randomized prospective comparison of BCG versus C. parvum adjuvant immunotherapy in melanoma patients with resected metastatic lymph nodes [Abstract]. Proc Am Soc Clin Oncol 1984; 3:263.
12. Lipton A, Harvey HA, Balch CM, et al.: Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 1991; 9:1151-1156
13. Balch CM, Smalley RV, Bartolucci AA, et al.: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I) prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982; 49:1079-1084.
14. Hansson J, Ringborg U, Lagerlof B, Strander H: Adjuvant chemotherapy of malignant melanoma. A pilot study. Am J Clin Oncol 1985; 8:47-50.
15. Lejeune FJ, Macher E, Kleeberg U, et al.: An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin. A phase II adjuvant study. (EORTC protocol 18761). Eur J Cancer 1988; 24:S81-S90.
16. Hill GJ 2nd, Moss SE, Golumb FM, et al.: DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040. Cancer 1981; 47:2556-2562.
17. Karakousis CP, Emrich LJ: Adjuvant treatment of malignant melanoma with DTIC+ estracyt or BCG. J Surg Oncol 1987; 36:235-238.
18. Banzet P, Jacquillat C, Civatte J, et al.: Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 1978; 41:1240-1248.
19. Meisenberg BR, Ross M, Vredenburgh JJ, et al.: Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for hish-risk, multi-node-positive malignant melanoma. J Natl Cancer Inst 1993; 85:1080-1085.
20. Spitler LE, Sagebiel R: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. N Engl J Med 1980; 303:1143-1147.
21. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J Clin Oncol 1991; 9:736-740.
22. Quirt IC, Shelley WE, Pater JL, et al.: Improved survival in patients with poor-prognosis malignant melanoma: a phase III study by the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 1991; 9:729-735.
23. Parkinson DR: Levamisole as adjuvant therapy for melanoma: Quo vadis? [editorial]. J Clin Oncol 9:736-717, 1991
24. Moertel CG, Fleming TR, Macdonald JS, et al.: Levamisole and fiuorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358.
25. Meyskens FL Jr.: The endocrinology of malignant melanoma. Rev Endo Rel Cancer 1981; 9:5-13.
26. Shaw HM, McGovern VJ, Milton GW, et al.: The female superiority in survival in clinical stage II cutaneous malignant melanoma. Cancer 1982; 49:1941-1944.
27. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ: A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 1989; 12:152-155.
28. Rowland KM Jr, Loprinzi CL, Shaw EG, et al.: Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14:135-141.
29. Meyskens FL Jr, Liu PY, Tuthill RJ, et al.: Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group Study. J Clin Oncol 1994; 12:2060-2065.
30. Isaacs A, Lindemann JJ: Virus interference: the interferon. Proc R Soc (Lond) 1957; 147:258-267.
31. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
32. Kirkwood JM, Strawderman MH, Ernstoff MS, et al.: Adjuvant therapy of high risk melanoma: the role of high-dose interferon alfa-2b. In Salmon S (ed): "Adjuvant therapies of cancer, VIII." Philadelphia: Lippincott-Raven 1997; p. 251-257.
33. Cole BF, Gelber RD, Kirkwood JM, et al.: Aquality-of-life-adjusted survival anaysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684). J Clin Oncol 1996; 14:2666-2673.
34. Hillner BE, Kirkwood JM, Atkins MB, et al.: Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997; 15:2351-2358.
35. Creagan ET, Dalton RJ, Ahmann DL, et al.: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995; 13:2776-2783.
36. Cascinelli N, Bufalino R, Morabito A, Mackie R: Results of adjuvant interferon study in WHO melanoma programme [letter] [comment in Lancet 1994; 343:1498-1499]. Lancet 1994; 343(8902): 913-914.
37. Cascinelli N: Evaluation of efficacy of adjuvant rIFNa 2A in melanoma patients with regional node metastases [Abstract]. Proc Am Soc Clin Oncol 1995; 14:A1296.
38. Hersh MR, Linn W, Kuhn JG, Von Hoff DD: Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy. Cancer Treat Rep 1986; 70:3:349-352.
39. Grob JJ, Dreno B, Delaunay M, et al.: Long term results of an adjuvant therapy with low doses IFN-alpha2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases [Abstract] Melanoma Res 1997; 7:S33
40. Meyskens FL Jr, Kopecky K, Samson M, et al.: Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma [letter]. J Natl Cancer Inst 1990; 82:1071.
41. Meyskens FL Jr, Kopecky KJ, Taylor CW, et al.: Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group Study. J Natl Cancer Inst 1995; 87:1710-1713.
42. Bystryn JC, Ferrone S, Livingston P, et al.: "Specific immunotherapy of cancer with vaccines." New York: New York Academy of Sciences; 1993.
43. Springer GF, Desai PR, Tegtmeyer H, et al.: Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast cancer recurrence. Ann N Y Acad Sci 1993; 690:355-357.
44. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8:1858-1867.
45. Cassel WA, Murray DR, Phillips HS: A phase II study on the post-surgical management of stage II malignant melanoma with a Newcastle disease virus oncoloysate. Cancer 1983; 52:856-860.
46. Wallack MK, Sivanandham M, Balch CM, et al.: A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34-42
47. Mitchell MS, Harel W, Kempf RA, et al.: Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8:856-869.
48. Livingston PO, Wong GV, Adluri S, et al.: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganalioside. J Clin Oncol 1994; 12:1036-1044.
49. Livingston PO: The case for melanoma vaccines that induce antibodies. In Kirkwood JM (ed): "Molecular diagnosis and treatment of melanoma." New York: Marcel Dekker, 1997.
50. van der Bruggen P, Bastin J, Gajewski T, et al.: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24:3038-3043.
51. Lotze MT, Storkus WJ, Hurd SD, et al.: Immunotherapy of melanoma. Melanoma Res 1993; 3:5-6.
52. Murphy GF: Cytokeratin typing of cutaneous tumors: a new immunochemical probe for cellular differentiation and malignant transformation [editorial]. J Invest Dermatol 1985; 84:1-2.
53. Allan SG, Hay FG, McIntyre MA, Leonard RC: Prognosis in small cell carcinoma of the lung - relationship to human milk fat globule 2 (HMFG2) antigen and the other small cell associated antigens. Br J Cancer 1987; 56:485-488.
54. Pfizenmaier K, Bartsch H, Scheurich P, et al.: Differencial gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Cancer Res 1985; 45:3503-3509.
55. Kalofonos HP, Sivolapenko G, Courtenay-Luck N, et al.: Antibody guided targetting of non- small cell lung cancer using Indium-1I1 HMFG1-F(ab′)2 fragments [Abstract]. Br J Cancer 1987; 56:530.
56. Larizza L, Schirrmacher V, Graf L, et al.: Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage. Int J Cancer 1984; 34:699-707.
57. Arcangeli G, Righini R, Nervi C, et al.: Pilot study of multiple-fraction daily radiotherapy alternating with chemotherapy in patients with stage IV non-oat cell lung cancer. Cancer Treat Rep 1985; 69:25-31.